BMS 986218
Alternative Names: Anti-CTLA-4 NF - Bristol-Myers Squibb; BMS-986218Latest Information Update: 17 Oct 2024
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Columbia University; Ferring Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer; Solid tumours
Most Recent Events
- 08 Sep 2024 Efficacy and adverse events data from the Neo-Red-P phase I trial in Prostate cancer presented at CRI-ENCI: 8th Annual International Cancer, Immunotherapy Conference(CICON-2024)
- 02 May 2024 Bristol-Myers Squibb terminates a phase I/II trial in Solid tumours (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Belgium, Canada, Israel, Finland, Netherlands, Norway, Poland, Spain, Germany, Italy, Argentina, Chile, France, Romania, Switzerland, Finland (IV) due to change in business objectives (NCT03110107) (EudraCT2017-000597-11)
- 05 Apr 2024 Efficacy and adverse events data from the Neo-Red-P phase I trial in Prostate cancer presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)